Medical imaging advanced analytics company IXICO (AIM: IXI) announced on Wednesday that it is collaborating with IMEKA Solutions Inc to provide access to Imeka's white matter imaging services for Alzheimer's Disease (AD) and Multiple Sclerosis (MS) clinical trials, among other CNS indications.
The collaboration streamlines procurement processes for IXICO's global biopharma clients, enhancing access to advanced AI tools for white matter imaging.
White matter imaging is increasingly vital for neuroinflammation and axonal integrity assessments in AD and MS clinical trials, along with other CNS indications.
IXICO aims to revolutionise neurological disease therapy advancements by providing valuable insights through data analytics and AI-driven medical image analysis.
The company's remote access technology platform enables scalable data analytics deployment, optimising drug development investments and reducing clinical trial risks for pharmaceutical clients.
Imeka, a leader in white matter microstructure imaging, offers advanced MRI processing and AI capabilities to facilitate novel insights for research and clinical communities.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration